TBC1D17

Across TCGA pan-cancer cohorts, TBC1D17 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TBC1D17 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TBC1D17 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TBC1D17 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where TBC1D17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.659	0.411	<.001	66	view →
HNSC	OS	Tertile	All	0.960	0.817	.005	24	view →
GBM	OS	Median	All	0.507	0.268	.009	13	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LUAD	OS	Tertile	II,III,IV	0.833	0.324	.013	6	view →
UCEC	OS	Tertile	III,IV	0.357	1.000	.042	4	view →
LSCC	DFS	Quartile	II,III,IV	0.522	0.859	.037	2	view →
CCRCC	DFS	Quartile	II,III,IV	0.754	0.435	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TBC1D17–PDAC (OS)

Open the PDAC breakdown →